louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02449772: Emergency Department (ED) Triage of Alcohol Abuse
Official title: Evaluation of ED Triage of Adult Patients With Alcohol Abuse
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alcoholic Intoxication
Keywords: N04.452.442.422.336
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
First posted: 2015-05-20
Enrollment: 775
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all adult patients admitted during one year in the ED for alcoholic abuse

Brief summary: Retrospective study of adult patients (\> 16 y) admitted to Geneva University Hospitals with alcohol abuse. Triage criteria will be reviewed. Patients characteristics and patient flow in the ED will be described.

Detailed description: A retrospective analysis of triage notes and electronic medical records will be performed in order to identify how triage evaluation is performed accordingly to the Swiss Emergency Triage Scale criteria. The proportion of patients leaving without being seen will be computed. Caracteristics of these patients will be compared to patients with medical evaluation.

Eligibility criteria: Inclusion Criteria:

* Triage code = alcohol abuse
* \> 16 y

Exclusion Criteria:

* No alcohol abuse identified at triage
* \< 16 y

Primary outcomes:
measure: Triage questions asked
timeFrame: participants will be followed for the duration of emergency department stay, an expected average of 12 hours
measure: Triage vital signs measured
timeFrame: participants will be followed for the duration of emergency department stay, an expected average of 12 hours
measure: Number of undertriage
timeFrame: participants will be followed for the duration of emergency department stay, an expected average of 12 hours
measure: Number of mistriage
timeFrame: participants will be followed for the duration of emergency department stay, an expected average of 12 hours
Secondary outcomes:
measure: % of patients leaving without being seen
timeFrame: participants will be followed for the duration of emergency department stay, an expected average of 12 hours
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva University Hospitals, ED
Study officials:
affiliation: University Hospital, Geneva
name: Olivier T Rutschmann, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dugas S, Favrod-Coune T, Poletti PA, Huwyler T, Richard-Lepouriel H, Simon J, Sarasin FP, Rutschmann OT. Pitfalls in the triage and evaluation of patients with suspected acute ethanol intoxication in an emergency department. Intern Emerg Med. 2019 Apr;14(3):467-473. doi: 10.1007/s11739-018-2007-7. Epub 2018 Dec 14.
Clinical trial NCT02384772: Survey of Patients Taking IOP-Lowering Eye Drops
Official title: A Multi-Site Questionnaire-Based Study to Assess Attitudes Regarding Current IOP-Lowering Eye Drops and Products in Development for Sustained Release of Medication in Glaucomatous and Ocular Hypertensive Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma
Ocular Hypertension
Lead sponsor: ForSight Vision5, Inc.
Sponsor class: INDUSTRY
First posted: 2015-03-10
Enrollment: 160
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients prescribed IOP-lowering eye drops.

Brief summary: Survey to assess perspectives of patients prescribed IOP-lowering eye drops at a single office visit.


Eligibility criteria: Inclusion Criteria:

* Prescribed IOP-lowering eye drops

Exclusion Criteria:

* Can complete survey instrument in English

Primary outcomes:
measure: Descriptive Statistics of Subject Perceptions of Different IOP-Lowering Treatments
timeFrame: A Single Office Visit
Secondary outcomes:
Other outcomes:
Locations:
city: Menlo Park
country: United States
facility: ForSight VISION5 Recruitment Referral Center
state: California
Study officials:
References:
Clinical trial NCT00606372: On-Pump vs. Off-Pump CABG in High-Risk Patients (EuroSCORE 6+)
Official title: Aortocoronary Bypasses in High-Risk Patients (EuroSCORE 6+) With or Without Use of the Cardio-Pulmonary Bypass.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ischemic Heart Disease
Post-Operative Complications
Keywords: Off-pump
OPCAB
EuroSCORE
high-risk patients
Quality of life
Validity of EuroSCORE
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
First posted: 2008-02-04
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: People indicated for surgical myocardial revascularisation with high surgical risk

Brief summary: Previous studies comparing on-pump and off-pump operating strategy did only partially demonstrate benefits of the off-pump myocardial revascularisation.In primary end-points (MI, death, renal failure, and so on) there was no significant difference, but in secondary end-points we observed benefits resulting for patients. We would like to show the benefit of the method without extracorporeal circulation in patients with higher and hight operation risk, coming from EuroSCORE classification system (6 points and more).


Eligibility criteria: Inclusion Criteria:

* stable form of ischemic heart disease
* unstable angina pectoris
* acute myocardial infarction
* additive EuroSCORE 6 and more
* informed approval of the patient

Exclusion Criteria:

* significant heart valve disease, requesting surgery
* aortic aneurysm requesting surgery

Primary outcomes:
measure: death, heart stroke, brain stroke, renal failure, early reoperation
timeFrame: 30 days
measure: heart stroke, brain stroke, death, renal failure, early reoperation
timeFrame: 30 days and 365 days
Secondary outcomes:
measure: length of in-hospital stay, blood losses, number of blood-transfusion, new appeared atrial fibrillation, 1-year mortality, quality of life-angina classified by CCS in 1-year follow up, length of mechanical ventilation
timeFrame: 30 days and 365 days
Other outcomes:
Locations:
city: Prague
country: Czech Republic
facility: Kralovske Vinohrady University Hospital
city: Prague
country: Czech Republic
facility: 2nd Surgical Dpt. of 1st Faculty of Medicine of Charles University, Prague
Study officials:
affiliation: Charles University, Prague
name: Zbynek Straka, 1
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02640872: A Prospective Cohort Study of Aged People for Chronic Diseases
Official title: A Hospital-based Prospective Cohort Study With Aged People to Elucidate Predictive Factors Including Muscle and Fat Mass for Chronic Diseases and Mortality
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Sarcopenia
Keywords: sarcopenia
sarcopenic obesity
osteoporosis
fracture
cardiovascular disease
mortality
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2015-12-29
Enrollment: 1000
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Aged 60 years and older Capable of communication with the research team Provided written informed consent

Brief summary: This study is a hospital-based, prospective cohort study to elucidate the predictive factors including muscle and fat mass for chronic diseases and mortality in elderly persons aged 60 years and older.

Detailed description: This study is a hospital-based, prospective cohort study to elucidate the predictive factors among anthropometric and biochemical parameters and body composition information for chronic diseases including diabetes mellitus, myocardial infarction, stroke, osteoporosis, fracture, and cognitive dysfunction, and mortality in elderly persons aged 60 years and older.

Eligibility criteria: Inclusion Criteria:

* Aged 60 years and older
* Capable of communication with the research team
* Provided written informed consent

Exclusion Criteria:

* Age \< 60 years
* active malignancy
* uncompensated liver cirrhosis
* ESRD
* severe cognitive impairment which cannot communicate with the research term

Primary outcomes:
measure: Alll cause mortality
timeFrame: 9 years
Secondary outcomes:
measure: Cardiometabolic mortality
timeFrame: 9 years
measure: Incidence of major adverse cardiac event including nonfatal myocardial infarction, nonfatal stroke, and unstable angina
timeFrame: 9 years
measure: Incidence of frailty defined by the Korean Fraility Index
timeFrame: 9 years
measure: Incidence of osteoporotic fracture
timeFrame: 9 years
measure: Incidence of cognitive dysfunction measured by minimental status examination
timeFrame: 9 years
measure: Development of sarcopenia defined by the Foundation for the National Institutes of Health (FNIH) criteria
timeFrame: 9 years
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi
Study officials:
affiliation: SNUBH
name: Soo Lim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03203772: Immersive Virtual Reality for Neuropathic Pain
Official title: Management of Pain in Limb Neuropathic Conditions Through Immersive Virtual Reality
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neuropathy
Phantom Limb Pain
Complex Regional Pain Syndromes
Neuropathic Pain
Lead sponsor: Loma Linda University
Sponsor class: OTHER
First posted: 2017-06-29
Enrollment: 14
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Investigating how neuropathic limb pain, including phantom limb pain or complex regional pain syndrome, is affected by virtual reality. While several studies have looked into virtual reality for treating this type of pain, few have used the latest immersive virtual reality hardware combined with motion control for an engaging virtual mirror therapy experience. The investigators are interested in studying the use of virtual reality as an alternative treatment option for these conditions.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of complex regional pain syndrome or phantom limb pain in an upper or lower limb

Exclusion Criteria:

* Cognitive impairment leading to inability to make own medical decisions
* Complete inability to utilize leg or arm muscles that are needed for motion controller tracking
* History of seizures within the last year

Primary outcomes:
measure: Feasibility of Virtual Reality Environment Use Questionnaire
timeFrame: Immediately following final virtual reality session
measure: Pain Relief with Virtual Reality Therapy: Wong-Baker Scale
timeFrame: Change from initial scores prior to virtual reality exposure to immediately prior to and following virtual reality sessions, and up to 8 weeks following last sessions
measure: Pain Relief with Virtual Reality Therapy: Visual Analog Scale
timeFrame: Change from initial scores prior to virtual reality exposure to immediately prior to and following virtual reality sessions, and up to 8 weeks following last sessions
measure: Pain Relief with Virtual Reality Therapy: Short-Form McGill Pain Scale
timeFrame: Change from initial scores prior to virtual reality exposure to immediately prior to and following virtual reality sessions, and up to 8 weeks following last sessions
Secondary outcomes:
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: Loma Linda University Health, East Campus Outpatient Rehabilitation Center
state: California
Study officials:
affiliation: Loma Linda Univeristy
name: Brian Chau, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06050772: Effect of Immersive Virtual Reality Reminiscence Versus Traditional Reminiscence Therapy on Cognitive Function and Psychological Wellbeing Among Institutionalized Older Adults: A Randomized Controlled Trial
Official title: Effect of Immersive Virtual Reality Reminiscence Versus Traditional Reminiscence Therapy on Cognitive Function and Psychological Wellbeing Among Institutionalized Older Adults: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Institutionalized Older Adults
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2023-09-22
Enrollment: 60
Sex: ALL
Minimum age (years): 60
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Cognitive function and psychological wellbeing are basic determinants of successful ageing that enable older adults to maintain their health, independence, and autonomy. Reminiscence therapy (RT) is one of the most prevalent evidence-based psychosocial interventions that can enhance older adults' cognitive function and maintain their psychological health. Virtual reality (VR) reminiscence is an innovative strategy that has the advantage of integrating technology in to the care of institutionalized older adults. However, limited researches have been conducted to compare the role of VR reminiscence versus traditional RT on improving older adult's cognitive and psychological wellbeing.

Detailed description: The aim of this study is to determine the effect of virtual reality reminiscence versus traditional reminiscence therapy on cognitive function and psychological wellbeing among institutionalized older adults.

Eligibility criteria: Inclusion Criteria:

* their age is 60 years and above, capable of communicating clearly, free form hearing or vision impairments that might hinder RT, and being able to tolerate using the Head Mounted Display(HMD) headset.

Primary outcomes:
measure: cognitive function
timeFrame: 3 months
measure: Psychological Wellbeing
timeFrame: 3 months
measure: Virtual Reality
timeFrame: 3 months
measure: Immersive Virtual Reality
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Damanhūr
country: Egypt
facility: Faculty of Nursing, Damnhour university
Study officials:
References:
Clinical trial NCT01808872: Clinical Performance Evaluation of AQT90 FLEX BNP and NT-proBNP
Official title: Clinical Sensitivity and Specificity Study of AQT90 FLEX BNP and NT-proBNP
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Failure
Lead sponsor: Radiometer Medical ApS
Sponsor class: INDUSTRY
First posted: 2013-03-11
Enrollment: 569
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects 21 years of age or older with heart failure

Brief summary: The AQT90 FLEX B-type Natriuretic Peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP) Tests are in vitro diagnostic assays intended as an aid in the diagnosis and assessment of the severity of heart failure in point-of-care and laboratory settings. The purpose of the study is to establish the clinical performance of the AQT90 FLEX BNP and NT-proBNP assays for both whole blood and plasma in the intended use population.


Eligibility criteria: Inclusion Criteria:

* Subject is 21 years of age or older
* Subject is able to understand information given, and willing and able to voluntarily give their consent to participate in this study
* Subject has diagnosis of heart failure

Exclusion Criteria:

* Subject has Acute Coronary Syndrome (ACS)
* Subject has been diagnosed and/or treated for malignancy within past 6 months
* Subject has had cardiac surgery within the past 4 weeks
* Subject claim of pregnancy
* Subject's prior participation in this study

Primary outcomes:
measure: Determination of the clinical sensitivity and specificity of the AQT90 FLEX BNP and NT-proBNP assays at the clinical cut-off in heart failure patients
timeFrame: Single blood draw upon study entry
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University
state: North Carolina
Study officials:
References:
Clinical trial NCT02298972: Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer
Official title: Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Chemotherapy
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: Flemish League Against Cancer
First posted: 2014-11-24
Enrollment: 143
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study evaluates the value of a nursing symptom support en selfmanagement intervention for adult patients with cancer treated with chemotherapy. Using a prospective sequential design with a comparison group who receives standard care and a (later) intervention group who gets the nursing intervention, we will evaluate the effect of this nursing intervention on overall symptom distress (primary outcome) and other measures of symptom burden, self-efficacy, outcome expectations and self-care. By conducting sem-structured interviews with some participants of the intervention group, we will study the patient experience of the intervention.


Eligibility criteria: Inclusion Criteria:

* Patients starting first line treatment with (intravenous) chemotherapy
* Ambulatory patients or patients who receive their treatment during short hospital stays
* Regardless of type of cancer, treatment or treatment intention (curative or palliative)
* Who understand sufficiently Dutch to fill out questionnaires
* Who sign informed consent for their participation in the study

Exclusion Criteria:

* Oral anticancer treatment
* Concomitant chemoradiotherapy
* Breast cancer patients who receive nurse counseling throughout their therapy
* Experimental therapy in the context of a clinical trial

Primary outcomes:
measure: Overall symptom distress
timeFrame: Longitudinal, during first 3 months after start of treatment
measure: Overall symptom severity
timeFrame: Longitudinal, during first 3 months after start of treatment
Secondary outcomes:
measure: Total self-efficacy score
timeFrame: Day 43 of treatment (+/- 1 week)
measure: Total outcome expectations score
timeFrame: Day 43 of treatment (+/- 1 week)
measure: Total self-care score
timeFrame: Day 85 of treatment (+/- 1 week)
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: UZ Leuven
Study officials:
References:
Clinical trial NCT06791772: Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
Official title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM313(SC) Injection in Subjects With Systemic Lupus Erythematosus
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Systemic Lupus Erythematosus
Lead sponsor: Keymed Biosciences Co.Ltd
Sponsor class: INDUSTRY
First posted: 2025-01-24
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)


Eligibility criteria: Inclusion Criteria:

1. Males or females aged 18 to 65 years.
2. Voluntarily signed the informed consent form (ICF).
3. Patients were diagnosed with systemic lupus erythematosus(SLE) according to the diagnostic classification criteria of the European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) in 2019.
4. Systemic Lupus Erythematosus Disease Activity Index - 2000(SLEDAI-2K) score ≥6 during screening, and SLEDAI-2K clinical score (except for low complement and/or positive anti-dsDNA antibodies) ≥4 during screening and at baseline.
5. Positive antinuclear antibody and/or anti-dsDNA antibody results defined in accordance with the laboratory reference value range of the Central laboratory during the screening.
6. ≥1British Isles Lupus Assessment Group-2004 (BILAG-2004) organ system rated as A or ≥ 2 organ system rated as B, and Physician's Global Assessment(PGA) score ≥1.0 during screening.
7. Maintain a stable standard treatment regimen for at least 30 days prior to initial dosing of the investigational product.

Exclusion Criteria:

1. Kidney disease: Severe lupus nephritis within within 8 weeks prior to randomization.
2. Patients with systemic lupus erythematosus(SLE) or non-SLE related central nervous system disease within 8 weeks prior to randomization.
3. There were non-SLE inflammatory skin or joint diseases that the investigators thought might be evaluated during the screening period.
4. History of clinically significant diseases.

Primary outcomes:
measure: Proportion of subjects achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)
timeFrame: Up to week 24
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Xiaofeng Zeng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06191172: The Effect of Person-Centered Care Applied to Patients With Dementia on Nutritional Status
Official title: The Effect of Person-Centered Care Applied to Patients With Dementia on Nutritional Status
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Dementia
Keywords: dementia
person-centered
Edfed
feeding difficulty
Lead sponsor: Istanbul University - Cerrahpasa
Sponsor class: OTHER
First posted: 2024-01-05
Enrollment: 55
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of this study is to examine the effect of person-centered care on nutritional status of patients with dementia.

In this study, we think that since the practices that reduce the eating difficulties of patients with dementia and prevent possible problems will be applied in a person-centered manner, a different perspective will be developed in this field and will affect the care of the patients more positively.

Detailed description: In line with the observations made and the patient\&#39;s wishes, Montessori application, landscaping, special equipment such as high-contrast colored crockery, flatware, and spill-free containers, positive communication, effectiveness Person-centered care interventions such as activities will be implemented and their effects on nutritional status will be evaluated (Pre-test - post-test).

test randomized control group experimental design). No intervention will be made to the control group, they will only be observed.

Eligibility criteria: Inclusion Criteria:

* Being over 65 years old,
* Being diagnosed with dementia
* Being able to step on the scale (no lower extremity loss)

Exclusion Criteria:

* Acute disease state (pneumonia),
* Patients with PEG,
* Patients with severe visual and hearing impairment,
* Mild dementia patients,
* Parkinson\&#39;s patients,
* Patients with head trauma

Primary outcomes:
measure: Edfed score
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Turkey
state: Sıslı
Study officials:
References: